德国DAX30指数6月12日（周五）收盘上涨414.47点，涨幅1.71%，报24624.36点； 英国富时100指数6月12日（周五）收盘上涨168.55点，涨幅1.64%，报10472.43点； 法国CAC40指数6月12日（周五）收盘上涨150.07点，涨幅1.83%，报8350.87点； 欧洲斯托克50指数6月12日（周五）收盘上涨125.40点，涨幅2.07%，报6182.36点； 西班牙IBEX35指数6月12日（周五）收盘上涨487.32点，涨幅2.66%，报18777.42点； 意大利富时MIB指数6月12日（周五）收盘上涨1005.76点，涨幅1.99%，报51510.50点。

CSRC Shanghai Regulatory Bureau deputy director Zhao Guofu said on June 12 that in the year since the '1+6' STAR Market reform package the market has accepted 59 new IPO filings, a sharp year-on-year rise. Twenty-four of the filings are unprofitable companies, accounting for over 40%. Regulators have steadily resumed applying the fifth set of listing standards to unprofitable firms and have accepted nine new filings under that standard. Guidance was also issued extending the fifth-standard coverage to commercial rocket firms.

Maiwei Biotech said the FDA has formally authorized its clinical trial application for injectable 6MW5311 for hematologic malignancies, including chronic myelomonocytic leukemia (CMML) and multiple myeloma.